Product Introduction
Gardasil 9 Injection 0.5ml is a vaccine designed to protect against the human papillomavirus (HPV), a sexually transmitted infection associated with various types of cancers and genital warts. Developed by Merck & Co., this vaccine is a recombinant, non-infectious shot, meaning it contains virus-like particles (VLPs) that mimic the HPV virus but cannot cause disease. Gardasil 9 specifically targets nine HPV types: 6, 11, 16, 18, 31, 33, 45, 52, and 58. Types 6 and 11 are commonly linked to genital warts, while the other types are associated with cervical, vulvar, vaginal, and anal cancers.
Gardasil 9 was first approved by the U.S. Food and Drug Administration (FDA) in 2014 and has since been widely recommended by health authorities globally. It represents a significant advancement over earlier versions of the vaccine, such as the original Gardasil, which covered only four HPV types. Gardasil 9 is administered via intramuscular injection, typically into the upper arm or thigh, and the standard dosage is 0.5ml per shot.
Uses of Gardasil 9 Injection 0.5ml
The primary use of Gardasil 9 is to prevent HPV-related diseases. The vaccine is approved for use in both males and females, generally starting from the age of 9 up to 45 years. Key uses include:
- Prevention of Cervical Cancer: By targeting HPV types 16 and 18, which cause approximately 70% of cervical cancer cases, Gardasil 9 plays a crucial role in reducing the incidence of this deadly disease.
- Prevention of Other HPV-related Cancers: Gardasil 9 also protects against HPV types linked to cancers of the vulva, vagina, anus, penis, and oropharynx.
- Prevention of Genital Warts: The vaccine helps prevent genital warts caused by HPV types 6 and 11.
- Prevention of Precancerous Lesions: By preventing HPV infection, Gardasil 9 reduces the risk of developing precancerous lesions, which can progress to cancer if left untreated.
The vaccine’s effectiveness is highest when administered before individuals are exposed to HPV, which is why it is recommended for preteens and teenagers. However, adults up to age 45 can also benefit from vaccination if they have not been previously exposed to all nine HPV types covered by the vaccine.
Benefits of Gardasil 9 Injection 0.5ml
The benefits of Gardasil 9 are extensive and multifaceted:
- Broad Protection: Gardasil 9 covers nine HPV types, providing broader protection than earlier vaccines. This wide coverage significantly reduces the risk of HPV-related diseases.
- Reduction in Cancer Incidence: By preventing infections with high-risk HPV types, Gardasil 9 directly contributes to lowering the incidence of cervical and other HPV-related cancers.
- Decreased Healthcare Costs: Preventing HPV infections and subsequent cancers and genital warts can lead to substantial savings in healthcare costs associated with treatment and management of these conditions.
- Improved Quality of Life: By preventing the physical, emotional, and financial burdens associated with HPV-related diseases, Gardasil 9 contributes to improved quality of life for vaccinated individuals.
- Herd Immunity: Widespread vaccination can lead to herd immunity, reducing the overall prevalence of HPV in the population and providing indirect protection to unvaccinated individuals.
Side Effects of Gardasil 9 Injection 0.5ml
Like any medical intervention, Gardasil 9 can cause side effects, although most are mild and temporary. Common side effects include:
- Injection Site Reactions: Pain, swelling, and redness at the injection site are the most commonly reported side effects. These reactions typically resolve within a few days.
- Fever: Some individuals may experience a mild fever after receiving the vaccine.
- Headache: Headaches are another relatively common side effect, usually mild and short-lived.
- Fatigue: Feeling tired or fatigued is reported by some recipients.
- Muscle or Joint Pain: Some individuals may experience muscle or joint pain after vaccination.
Rarely, more serious side effects can occur, such as:
- Allergic Reactions: Severe allergic reactions (anaphylaxis) are extremely rare but require immediate medical attention.
- Syncope: Fainting may occur, particularly in adolescents, shortly after the injection. It is recommended to sit or lie down for about 15 minutes after vaccination to prevent falls or injuries from fainting.
References
- Merck Sharp and Dohme Ltd, Electronic Medicines Compendium (EMC), [Revised on Mar 2021] [Accessed on 29th April 2023], https://www.medicines.org.uk/emc/files/pil.261.pdf
- Merck and Co Inc, US Food and Drug Administration, [Revised on 2015] [Accessed on 29th April 2023], https://www.fda.gov/files/vaccines,%20blood%20&%20biologics/published/Package-Insert—Cervarix.pdf
- L Cheng et al., Human Papilloma Virus vaccines: An updated review, [Published on 2020] [Accessed on 29th April 2023], https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7565290/
- F T Cutts, Human Papillomavirus and Cervarix Injections, [Published on 2007] [Accessed on 29th April 2023], https://pubmed.ncbi.nlm.nih.gov/18026629/
Disclaimer
Singhla Medicos’s primary intention is to ensure that its consumers get information that is reviewed by experts, accurate and trustworthy. The information and contents of this website are for informational purposes only. They are not intended to be a substitute for professional medical advice, diagnosis, or treatment. Please seek the advice of your doctor and discuss all your queries related to any disease or medicine. Do not disregard professional medical advice or delay in seeking it because of something you have read on Singhla Medicos. Our mission is to support, not replace, the doctor-patient relationship.
Reviews
There are no reviews yet.